Status:

WITHDRAWN

Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19.

Lead Sponsor:

Paulo Brofman

Collaborating Sponsors:

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Conditions:

COVID-19 Pneumonia

COVID-19

Eligibility:

All Genders

18-79 years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this study is evaluate the feasibility, safety and potential efficacy of an advanced cell therapy product for the treatment of patients with SARS-CoV-2 pneumonia.

Detailed Description

Forty patients with COVID-19 will receive an intravenous infusion of one dose of 1.000.000 umbilical cord mesenchymal cells per kilo of the patient. Twenty patients will receive a placebo (Ringer's la...

Eligibility Criteria

Inclusion

  • Both sexes;
  • aged 18 to 79 years old;
  • hospitalized patients;
  • radiological diagnosis of viral pneumonia;
  • virological diagnosis of SARS-CoV-2 infection;
  • with noninvasive ventilatory support;
  • C-reactive protein and ferritin above the reference value considered normal;
  • assent confirmed to participate in the study.

Exclusion

  • Contraindications for use of corticosteroids;
  • immunosuppressive, cytotoxic and antiviral treatment, experimental medications and chronic corticosteroid use;
  • morbid obesity (BMI\> 35);
  • multiple organ dysfunction syndrome;
  • pre-malignant neoplastic conditions with life expectancy lower than 1 year old;
  • pre-existing chronic illnesses like chronic dialysis kidney disease, chronic liver disease, congestive heart failure Class IV; pulmonary hypertension (WHO Class III/IV);
  • pre-existing or current thromboembolic pathology;
  • transplanted patients;
  • pre-existing severe allergic reaction;
  • history of HIV and tuberculosis;
  • enrollment in another clinical trial;
  • pregnancy or breastfeeding.

Key Trial Info

Start Date :

May 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 31 2023

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT05433298

Start Date

May 1 2022

End Date

March 31 2023

Last Update

February 10 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Paulo Roberto Slud Brofman

Curitiba, Paraná, Brazil, 80215200